The Zymark RapidTrace TM automated solid-phase exlraction system has been evaluated for use in the urine drug-testing laboratory. Methods for cocaine metabolite (benzoylecgonine) and opiates (codeine and morphine) are described and evaluated. The linearity, precision, accuracy, recovery, and carryover statistics of these analytical protocols are presenled. The advantages of extraction using the RapidTrace instead of solid-phase extraction with the manual vacuum manifold or liquid-liquid extraction methods are described.
Introduction
The 1986 U.S. government mandate (1) to include urine drug testing as one method of reducing drug abuse in employees of federal agencies and their contractors substantially increased the focus on improved analytical methodologies. For the first time, certification standards were established and proficiency testing programs were implemented to assure that laboratories performing this testing met certain established standards (2) . The method to be used by individual laboratories to meet these requirements was only described in general terms.
Forty-nine laboratories responded to a survey of the seventythree NIDA (National Institute for Drug Abuse)-certified laboratories and the nine Department of Defense (DOD) laboratories in 1991 (3) . This survey indicated that approximately 50% of laboratories responding used solid-phase extraction (SPE) for the analysis of cocaine metabolite (benzoylecgonine) and opiates (codeine and morphine). Other laboratories used traditional liquid-liquid extraction methods. The level of automation was surveyed. One laboratory was using the Zymate TM robotic system (Zymark Corporation, Hopkinton, MA). All DOD laboratories and one commercial laboratory were using the DuPont Prep-I TM centrifugal extraction system (Creative Technologies, Wilmington, DE). Vacuum manifolds were used by other *Aulh,ar to whom correspondence should be addrest.ed. respondents to accomplish solid-phase extractions. Liquidliquid extractions were performed manually.
There is great interest in most laboratories in increasing efficiency, and automation is the method most often discussed. Why then are we still employing labor-intensive manual liquidliquid methods which are subject to human error? Why are we still performing SPE with cumbersome vacuum manifolds which are difficult to control? Part of the answer is the cost of the automation equipment and another part is simply inertia. Analysts are trained to perform extractions in a certain way. This method is validated and documented. Changing the method to make it amenable to automation may require development ofa SPE procedure to replace an existing liquidliquid method. It may require modification of a solid-phase procedure. In both cases, extensive revalidation and documentation are required. This takes capital investment and personnel time that must be justified through improvements in efficiency and reliability. Laboratory managers are often reluctant to transfer methods to automated equipment because of reliability concerns. What happens if the equipment fails? How will this affect turnaround-time promises to clients?
In 1994, we approached Zymark Corporation with an idea for a simple automated device that would be reasonably priced and perform SPE faster than manual vacuum box methods. In consultation with Zymark, the design of a simple, modular, redundant system, the Zymark RapidTrace, was developed. One to ten identical modules are easily controlled from a personal computer using WindowsTM-based software. All common SPE steps, including cartridge conditioning, diluent addition to specimen, mixing of specimen, specimen application to the cartridge, column rinsing, column drying, and column elution, can be performed by each module. Waste collection is selectable, permitting automated separation of nonchlorinated organic, chlorinated organic, and aqueous solvents. The Rapid-Trace may be configured to accept 3-mL, 1-mL, or thin-disc cartridges from most suppliers. Each module occupies bench space of 61 cmx 10 cm and is 57 cm in height. A set of ten can achieve sample throughputs of 40-100 samples per hour, depending on the complexity of the extraction. Downtime during routine maintenance or repair can be minimized by quick substitution of one module with a replacement. This exchange takes less than 10 min. The complete set of Rapid-Trace modules then continues to perform extractions while repair or maintenance is performed on the module removed from active duty. The module can easily be exchanged within 24 h for a new or repaired module by sending the broken module back to Zymark. Because each module operates independently, lost time is further minimized if one module fails during an analysis. The remaining nine modules continue to run, unaffected by the broken module. Thus, 90% of the work will continue. A set of ten modules with a dedicated personal computer and software costs $85,200.
The ease of use and built-in reliability of the RapidTrace makes it ideal for the extraction of urine samples for drugs of abuse in a high-volume testing laboratory. Federal guidelines and generally accepted laboratory protocols for employee testing require all samples that screen positive for a drug of abuse to be confirmed by gas chromatography-mass spectrometry (GC-MS). This confirmation method requires that the drugs or drug metabolites be extracted from urine samples. Laboratories that receive thousands of urine samples per day are not uncommon and should expect to have hundreds of samples requiring extraction and further testing by GC-MS. In 1993, 2.3% (350,000) urine samples tested were positive for the cocaine metabolite benzoylecgonine, and 2.0% (300,000) were positive for either codeine or morphine (4) . A laboratory that screens 5000 samples per day should expect more than 200 to require extraction for benzoylecgonine or opiates. This makes these analytes ideal candidates for automation using the RapidTrace.
Experimental
Methods distributed by solid-phase cartridge manufacturers for use with vacuum manifolds to extract these drugs or drug metabolites were used as the starting point for method development on the RapidTrace. The different methods were evaluated with the goal of having both methods use a total of fewer than ten reagents. In this way, either method could be run on any module without changing reagents. Drug recovery was evaluated and methods were modified slightly to optimize recovery and minimize carryover of drug from one sample to another without increasing the analysis time significantly. The methods were also developed to minimize human manipulation to the extent possible.
Benzoylecgonine
Varian Bondelut Certify TM (Varian Sample Preparation Products, Harbor City, CA) extraction cartridges (3-mL) were chosen for extraction of benzoylecgonine from urine. The internal standard, benzoylecgonine-d3, was obtained from Radian Corporation (Austin, TX). Methanol, hydrochloric acid, methylene chloride, sulfuric acid, and ammonium hydroxide were obtained from Fisher Scientific (Fairlawn, NJ). Isopropanol was purchased from EM Science (Gibbstown, N J). Deionized water was produced with a Solution 2000 cartridge deionization unit (Solution Consultants, Jasper, GA). bis-(TrimethylsilyI)-trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane (TMCS) was obtained from Regis Technologies (Morton Grove, IL).
All solutions were prepared before beginning sample aliquoting. The prepared reagents were stable for at least one week when stored in tightly covered containers. The benzoylecgonine-d3 was diluted to 1.0 IJg/mL in 0.01N aqueous H.~SQ. Concentrated hydrochloric acid was diluted with deionized water to 0.1M. Mixed elution solvent was prepared using 800 mL methylene chloride, 200 mL isopropanol, and 20 mL concentrated ammonium hydroxide.
One milliliter of each urine specimen was transferred with a new pipette tip to a 13 x 100-ram disposable borosilicate test tube. Deuterated benzoylecgonine internal standard solution (10012L), deionized water (1 mL), and pH 6.0 phosphate buffer (2 mL) were added, and the solution was vortex mixed. The tubes were then transferred to the RapidTrace for extraction. Up to ten extraction columns were loaded into each module. The extraction procedure was recalled using the control software and loaded into each module. The procedure was then started, and the following steps were carried out. The solidphase column was conditioned with 3 mL methanol, 2 mL of deionized water, and 1 mL of pH 6.0 phosphate buffer. The sample was then loaded onto the column. Two cannula purges were then performed with 4 mL of deionized water, and the column was rinsed with two 3-mL methanol washes. A 5-mL air push was applied to push the methanol rinses completely through the column to waste. The benzoylecgonine was eluted from the column with 3 mL of mixed solvent. The cannula was then rinsed with 4 mL of methanol to remove any remaining traces of analyte. With ten modules in simultaneous use, 67 samples, controls, and standards may be extracted every hour.
The tubes were then removed from the RapidTrace, and the extracts were transferred to screw-top tubes and evaporated to dryness at 40~ using a TurboVap TM (Zymark Corporation). The benzoylecgonine was then derivatized with 50 t-~L of BSTFA plus 1% TMCS at 70~ for 30 rain. Samples were then analyzed directly using a Hewlett-Packard (Palo Alto, CA) 5988A GC-MS. Quantitation was performed by comparison of ion ratios of the nondeuterated and deuterated analogues in samples, spiked standards, and controls.
Opiates (codeine and morphine)
Confirm SPE (International Sorbent Technology, UK) extraction cartridges (3-mL) were chosen for the extraction of The solutions necessary for hydrolysis and extraction of codeine and morphine were prepared before beginning sample aliquoting. These prepared reagents were stable for at least one week when stored in tightly covered containers. The codeine-d3 and morphine-d3 were diluted to 1.0 pg/mL each in 0.01N aqueous H2SO 4. Acetate buffer (1M, pH 5.0) was prepared by dissolving 136 g of sodium acetate in deionized water with a total volume of 1000 mL. The pH was then adjusted to 5.0 by adding glacial acetic acid. Phosphate buffer was prepared at 0.1M, pH 6.0 by dissolving 6.8 g of dibasic sodium phosphate and 42.4 g of monobasic sodium phosphate in deionized water and diluting to a final volume of 2.0 L. Acetate buffer (0.1M, pH 4.0) was prepared by diluting 39 mL 1M potassium hydroxide with 1.5 L deionized water and then carefully adding 11.4 mL glacial acetic acid. This solution was then diluted to a final volume of 2.0 L. Hydrolysis reagent was prepared at a level of 5000 Fishman units per milliliter of 1.0M pH 5.0 acetate buffer with [3-glucuronidase (Patella vulgata). The hydrolysis Statistic reagent should be stored frozen until just prior to use. Mixed elution solvent was pre-Recovery pared using 800 mL methylene chloride, 200 mL isopropanol, and 20 mL concentrated ammonium hydroxide.
One milliliter of each urine specimen was transferred with a new pipette tip to a 13-x 100-mm disposable borosilicate test tube. Fifty microliters of deuterated codeine and morphine internal standard solution and 0.8 mL of [3-glucuronidase hydrolysis reagent were added and vortex mixed. The samples were incubated at 65~ for 3 h and then cooled to room temperature. Sodium hydroxide (0.2 mL, 1N), 1 mL deionized water, and 2 mL of phosphate buffer were added to each tube before vortex mixing. The tubes were then transferred to the RapidTrace for extraction. Up to ten extraction columns were loaded into each module. The extraction procedure was recalled using the control software and loaded into each module. The procedure was then started, and the following steps were carried out. The solid-phase column was conditioned with 3 mL methanol, 2 mL of deionized water, and 1 mL of pH 6.0 phosphate buffer. Four milliliters of sample was then loaded onto the column. Two cannula purges were performed with 4 mL of deionized water, and the column was rinsed with 2 mL of deionized water and 2 mL of pH 4.0 acetate buffer. The opiates were eluted from the column with 3 mL of mixed solvent. The cannula was then rinsed with 4 mL of methanol to remove any remaining traces of analyte. With 10 modules in simultaneous use, 65 samples, controls, and standards may be extracted each hour.
The tubes were then removed from the RapidTrace, and the extracts were transferred to screw-top tubes and evaporated to dryness at 40~ using a TurboVap (Zymark Corporation). The codeine and morphine were then derivatized with 50 pL 
Results
Spiked urine samples and purchased control materials were used to evaluate the extraction methods. The benzoylecgonine procedure was found to be linear up to 1000 ng/mL. The codeine and morphine procedures were linear up to 2500 ng/mL. The results from statistical evaluation of standard analyses performed in a single day and on multiple days are presented in Tables I and II. In addition to standard statistical analyses of these analytical methods, we evaluated the potential for analyte carryover from one sample to the next sample. This is of concern because the consequence of a positive result may be termination of employment. A false-positive result would also have very negative consequences for the laboratory making the incorrect report. Urine samples have been analyzed with spiked concentrations of benzoylecgonine of 100,000 ng/mL and in the 50,000-100,000 ng/mL range for codeine and morphine. The administrative cutoffs below which GC-MS positive results may not be reported under federal guidelines are 150 ng/mL for benzoylecgonine and 300 ng/mL for codeine and morphine. The amount of carryover must be determined if a very high positive specimen was followed by a negative urine specimen.
There are two places during the analysis protocol where spec-imens or their extracts come into contact with the same surfaces. The first is when the sample is removed from the test tube in the RapidTrace when the cannula aspirates the sample. The cannula, the tubing connected to it, and the syringe all come into contact with each specimen, standard, and control. The other place where carryover may occur is when the derivatized extract is actually injected by the autosampler into the GC-MS system. The same syringe is used to inject every sample. Urine samples spiked with high concentrations (100,000 ng/mL for benzoylecgonine and codeine and 50,000 ng/mL for morphine) were analyzed using the RapidTrace extraction followed by GC-MS analysis to evaluate the relative potential carryover from each source activity. A blank urine sample was extracted following the extraction of the high spike sample. After derivatization, the samples were reordered for GC-MS analysis. The extract of the blank urine sample that followed the high-spiked sample was run after a blank injection and prior to the high-spiked urine sample. A different blank was then run after the GC-MS analysis of the high-spiked urine sample itself. In this way, both potential sources of carryover may be isolated and measured independently. The results are presented in Table III .
In all cases the carryover was small enough that positive results would not occur above administrative cutoffs. In the case of benzoylecgonine, the RapidTrace contributed approximately three times the carryover that the GC-MS system contributed. In the case of codeine, the GC-MS system contributed about twice as much carryover as the extraction system, and in the case of morphine, the GC-MS system was the source of almost three times as much carryover as the extraction system.
Clearly these concentrations must be evaluated and experimentally determined for each analyte-analysis system. In our High technologist skill level required laboratory, we have instituted standard procedures to address the possibility of contamination from other samples in an analytical run. Positive urine samples must be reanalyzed from the original sample ifa very high positive precedes it in a run. The concentration above which a very high positive triggers reanalysis of a subsequent sample must be experimentally determined. Carryover in the gas chromatograph autosampler as well as carryover that may occur during extraction must be evaluated. This eliminates the possibility that carryover will cause reporting of a false-positive result.
Discussion
The automated extraction capability of the RapidTrace has clear advantages over manual liquid-liquid extraction protocols and manual vacuum manifold-based solid-phase procedures. Specific considerations are presented in Table IV . Human manipulations are kept to a minimum, which results in improved extraction reliability, improved precision and accuracy, and fewer errors. Analyst time is saved for value-added tasks rather than wasted on repetitive procedures. Faster overall analysis time is achieved. Less training of analysts is required.
